147 related articles for article (PubMed ID: 30198569)
21. The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists.
Bodur C; Kazyken D; Huang K; Ekim Ustunel B; Siroky KA; Tooley AS; Gonzalez IE; Foley DH; Acosta-Jaquez HA; Barnes TM; Steinl GK; Cho KW; Lumeng CN; Riddle SM; Myers MG; Fingar DC
EMBO J; 2018 Jan; 37(1):19-38. PubMed ID: 29150432
[TBL] [Abstract][Full Text] [Related]
22. Computational analysis of an autophagy/translation switch based on mutual inhibition of MTORC1 and ULK1.
Szymańska P; Martin KR; MacKeigan JP; Hlavacek WS; Lipniacki T
PLoS One; 2015; 10(3):e0116550. PubMed ID: 25761126
[TBL] [Abstract][Full Text] [Related]
23. mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci.
Kelsey I; Zbinden M; Byles V; Torrence M; Manning BD
Sci Rep; 2017 Nov; 7(1):16112. PubMed ID: 29170467
[TBL] [Abstract][Full Text] [Related]
24. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
[TBL] [Abstract][Full Text] [Related]
25. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
26. The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168.
Xie X; Hu H; Tong X; Li L; Liu X; Chen M; Yuan H; Xie X; Li Q; Zhang Y; Ouyang H; Wei M; Huang J; Liu P; Gan W; Liu Y; Xie A; Kuai X; Chirn GW; Zhou H; Zeng R; Hu R; Qin J; Meng FL; Wei W; Ji H; Gao D
Nat Cell Biol; 2018 Mar; 20(3):320-331. PubMed ID: 29403037
[TBL] [Abstract][Full Text] [Related]
27. SUMOylation of AMPKα1 by PIAS4 specifically regulates mTORC1 signalling.
Yan Y; Ollila S; Wong IPL; Vallenius T; Palvimo JJ; Vaahtomeri K; Mäkelä TP
Nat Commun; 2015 Nov; 6():8979. PubMed ID: 26616021
[TBL] [Abstract][Full Text] [Related]
28. TSC2 regulates microRNA biogenesis via mTORC1 and GSK3β.
Ogórek B; Lam HC; Khabibullin D; Liu HJ; Nijmeh J; Triboulet R; Kwiatkowski DJ; Gregory RI; Henske EP
Hum Mol Genet; 2018 May; 27(9):1654-1663. PubMed ID: 29509898
[TBL] [Abstract][Full Text] [Related]
29. AMPK and autophagy get connected.
Hardie DG
EMBO J; 2011 Feb; 30(4):634-5. PubMed ID: 21326174
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL.
Hutter G; Zimmermann Y; Rieken M; Hartmann E; Rosenwald A; Hiddemann W; Dreyling M
Leukemia; 2012 Nov; 26(11):2442-4. PubMed ID: 22552006
[No Abstract] [Full Text] [Related]
31. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer.
Kan JY; Yen MC; Wang JY; Wu DC; Chiu YJ; Ho YW; Kuo PL
Oncotarget; 2016 May; 7(21):31336-49. PubMed ID: 27150059
[TBL] [Abstract][Full Text] [Related]
32. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
33. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
34. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
35. The lysosome: a crucial hub for AMPK and mTORC1 signalling.
Carroll B; Dunlop EA
Biochem J; 2017 Apr; 474(9):1453-1466. PubMed ID: 28408430
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide CRISPR screens reveal multitiered mechanisms through which mTORC1 senses mitochondrial dysfunction.
Condon KJ; Orozco JM; Adelmann CH; Spinelli JB; van der Helm PW; Roberts JM; Kunchok T; Sabatini DM
Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33483422
[TBL] [Abstract][Full Text] [Related]
37. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology.
Green AS; Chapuis N; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Cell Cycle; 2011 Jul; 10(13):2115-20. PubMed ID: 21572254
[TBL] [Abstract][Full Text] [Related]
38. Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin.
Darido C; Georgy SR; Cullinane C; Partridge DD; Walker R; Srivastava S; Roslan S; Carpinelli MR; Dworkin S; Pearson RB; Jane SM
Cell Death Differ; 2018 Jun; 25(6):1146-1159. PubMed ID: 29238073
[TBL] [Abstract][Full Text] [Related]
39. The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling.
van Veelen W; Korsse SE; van de Laar L; Peppelenbosch MP
Oncogene; 2011 May; 30(20):2289-303. PubMed ID: 21258412
[TBL] [Abstract][Full Text] [Related]
40. Antagonistic control of muscle cell size by AMPK and mTORC1.
Mounier R; Lantier L; Leclerc J; Sotiropoulos A; Foretz M; Viollet B
Cell Cycle; 2011 Aug; 10(16):2640-6. PubMed ID: 21799304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
